黄芪注射液辅助治疗对慢性精神分裂症患者生物学的影响及疗效观察  

Effect of Astragalus Injection as an Adjunctive Therapy on the Biology in Patients with Schizophrenia and Its Clinical Efficacy

作　　者：全瑞国 李秉泉[1] 李丽琴[1] 王东明[1] 宋培义[1] 陈富仁 

机构地区：[1]内蒙古包头市第六医院,包头市014040

出　　处：《中国药房》2009年第9期701-703,共3页China Pharmacy

摘　　要：目的:观察黄芪注射液辅助治疗对慢性精神分裂症患者生物学的影响及临床疗效。方法:将100例慢性精神分裂症患者随机分为2组,其中观察组50例,在常规服用抗精神病药物治疗的基础上加用黄芪注射液静脉滴注,每天40mL,每个疗程7天,共4个疗程;对照组50例,仅常规服用抗精神病药物,不配合中药治疗,疗程同观察组。2组均辅用苯二氮类药,但不能辅用其它催眠类药物。结果:治疗后2组在心电图中QTc间期变化、血糖变化、疗效、PANSS总分及分量表分、副反应方面均存在显著性差异(P<0.05或P<0.01)。结论:黄芪注射液辅助治疗慢性精神分裂症可提高疗效、降低副反应。OBJECTIVE： To observe the effect of Astragalus injection as an adjunctive therapy on the biology in patients with schizophrenia and its clinical efficacy. METHODS： A total of 100 patients with schizophrenia were randomly assigned to trial group（ n = 50） or control group（ n= 50） . The trial group received routine antipsychotic drugs plus Astragalus injection （40 mL· d^-1, iv gtt） for 7 days, and the control group received antipsychotic drugs alone without addition of traditional Chinese medicine for 7 days. All the patients received for a total of 4 courses of treatment. Besides, both groups received additional benzodiazepine but not other hipnotics. RESULTS： After treatment, there were significant differences between the trial group and the control group in ECG QTc duration, sugar level, therapeutic efficacy, PANSS scores （total score and the subitem scores） and adverse reactions etc（P 〈 0.05 or P 〈 0.01） . CONCLUSION： Astragalus injection as an adjunctive therapy can enhance the clinical efficacy for schizophrenia while lowering side effects.

关 键 词：黄芪注射液 慢性精神分裂症 生物学 临床疗效 辅助治疗 

分 类 号：R283.611[医药卫生—中药学] R749.3[医药卫生—中医学]